Status:

RECRUITING

Ultra-Protective Lung Ventilation With Extracorporeal CO2 Removal for Moderate ARDS

Lead Sponsor:

University of Bologna

Collaborating Sponsors:

Getinge Group

Conditions:

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

18-100 years

Phase:

NA

Brief Summary

Acute respiratory distress syndrome (ARDS) accounts for 10% of all ICU admissions and for 23% of patients requiring mechanical ventilation (MV). Its hospital mortality remains high, ranging from 34% i...

Detailed Description

Acute respiratory distress syndrome (ARDS) represents a form of lung injury that occurs in response to various predisposing events, characterized by inflammation, increased pulmonary vascular permeabi...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • On invasive mechanical ventilation for ≤ 96 hours
  • Presence of all of the following conditions for ≤ 24 hours: 100 \< PaO2/FiO2 ≤ 200 after 12 hours of "standardized ventilation" with PEEP ≥ 5; compliance of the respiratory system ≤ 0.5 ml/cmH2O per kg PBW; ventilatory ratio (VR) ≥ 1.5; bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload

Exclusion

  • Pregnancy
  • ARDS with PaO2/FiO2\<100 or PaO2/FiO2\>200 under standardized ventilation with PEEP ≥ 5 cmH2O
  • Expected duration of mechanical ventilation \< 48 hours
  • Severe COPD
  • Chronic respiratory insufficiency with home ventilation or oxygen therapy
  • Currently receiving ECMO therapy
  • Acute brain injury
  • Severe liver insufficiency (Child-Pugh scores \>7) or fulminant hepatic failure
  • Heparin-induced thrombocytopenia
  • Contraindication for systemic anticoagulation
  • Platelet count \<50,000/mm3
  • Prothrombin time-international normalized ratio (INR) \>1.5
  • Patient moribund, decision to limit therapeutic interventions
  • End-stage disease
  • Unable to provide vascular access for ECCO2-R
  • Acute coronary syndrome
  • Actual body weight exceeding 1 kg per centimeter of height
  • Burns \> 40% total body surface
  • Bone marrow transplantation within the last 1 year

Key Trial Info

Start Date :

December 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 31 2027

Estimated Enrollment :

230 Patients enrolled

Trial Details

Trial ID

NCT04903262

Start Date

December 1 2024

End Date

March 31 2027

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS AOUBO Policlinico di Sant'Orsola

Bologna, Italy